- Home
- XPEV vs UTHR Comparison
XPEV vs UTHR Comparison
Compare XPEV & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPEV
- UTHR
- Stock Information
- Founded
- XPEV 2015
- UTHR 1996
- Country
- XPEV China
- UTHR United States
- Employees
- XPEV N/A
- UTHR N/A
- Industry
- XPEV Auto Manufacturing
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- XPEV Consumer Discretionary
- UTHR Health Care
- Exchange
- XPEV Nasdaq
- UTHR Nasdaq
- Market Cap
- XPEV 21.7B
- UTHR 20.7B
- IPO Year
- XPEV 2020
- UTHR 1999
- Fundamental
- Price
- XPEV $21.19
- UTHR $432.86
- Analyst Decision
- XPEV Buy
- UTHR Buy
- Analyst Count
- XPEV 8
- UTHR 15
- Target Price
- XPEV $22.51
- UTHR $466.73
- AVG Volume (30 Days)
- XPEV 7.7M
- UTHR 760.6K
- Earning Date
- XPEV 11-18-2025
- UTHR 10-29-2025
- Dividend Yield
- XPEV N/A
- UTHR N/A
- EPS Growth
- XPEV N/A
- UTHR 17.94
- EPS
- XPEV N/A
- UTHR 25.63
- Revenue
- XPEV $8,416,181,216.00
- UTHR $3,077,800,000.00
- Revenue This Year
- XPEV $99.57
- UTHR $13.71
- Revenue Next Year
- XPEV $39.79
- UTHR $5.72
- P/E Ratio
- XPEV N/A
- UTHR $16.90
- Revenue Growth
- XPEV 66.37
- UTHR 17.62
- 52 Week Low
- XPEV $10.07
- UTHR $266.98
- 52 Week High
- XPEV $27.16
- UTHR $459.48
- Technical
- Relative Strength Index (RSI)
- XPEV 44.34
- UTHR 56.87
- Support Level
- XPEV $20.81
- UTHR $427.86
- Resistance Level
- XPEV $22.13
- UTHR $441.78
- Average True Range (ATR)
- XPEV 0.81
- UTHR 10.76
- MACD
- XPEV -0.29
- UTHR -5.17
- Stochastic Oscillator
- XPEV 11.94
- UTHR 37.14
About XPEV XPeng Inc.
Founded in 2015, XPeng is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 190,000 EVs in 2024, accounting for about 2% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.